DGX vs RVTY — Key Metrics
| Metric | DGX (QUEST DIAGNOSTICS INC) | RVTY (REVVITY INC) |
|---|---|---|
| Price | 259.69 | 152.43 |
| Market Cap | 28.57 Billion | 17.02 Billion |
| P/E (TTM) | 25.51 | 67.75 |
| P/B (Quarterly) | 3.487 | 2.443 |
| P/S (TTM) | 2.41 | 5.78 |
| Net Profit Margin (TTM) | 9.5 | 8.6 |
| Gross Margin (TTM) | 33.1 | 55.9 |
| ROE (TTM) | 15.2 | 3.5 |
| Revenue Growth YoY (TTM) | n/a | n/a |
Upfront Investment - S&P 500 Stock Comparison & AI Analysis
AI-powered analysis and comparison tools for S&P 500 stocks, helping investors make data-driven decisions with delayed market data and portfolio modeling.
Performance Comparison
AI Model Recommendation
Underperform
Underperform
Recommendation Summary
Both stocks are projected to underperform the market over the next year. If you have to make a choice, Upfront Recommendation: DGX.
Financial Metrics
| DGX | Metrics | RVTY |
|---|---|---|
| $259.69 | Price | $152.43 |
| — | Market Capitalization | — |
| 25.51 | Price to Earnings Ratio | 67.75 |
| 2.41 | Price to Sales | 5.78 |
| 20.78 | Price to FCF Ratio | 28.24 |
| 7.29 | Price to Gross Profit | 10.35 |
| 9.17 | Price to Current Assets | 9.14 |
DGX vs RVTY at a glance
Quest Diagnostics INC (DGX) and Revvity INC (RVTY) are both Diagnostics & Research companies in the Healthcare sector. DGX is the larger, at $28.6 billion in market value against $17.0 billion for RVTY, about 1.7 times the size.
On trailing-twelve-month figures, DGX trades at 25.5 times trailing earnings and RVTY at 67.8; net profit margins are 9.5% and 8.6%.
The Upfront Investment model currently rates both Underperform as of November 18, 2026. The rating ranks the model's medium-term return forecast against the other stocks it scores; it is a statistical forecast, not investment advice.